Announcement • May 18
Cravatex Limited, Annual General Meeting, Jul 31, 2026 Cravatex Limited, Annual General Meeting, Jul 31, 2026. Declared Dividend • May 18
Dividend increased to ₹13.00 Dividend of ₹13.00 is 4.0% higher than last year. Ex-date: 24th July 2026 Payment date: 30th August 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but not covered by cash flows (370% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 26% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 16
Cravatex Limited announces Annual dividend, payable on August 30, 2026 Cravatex Limited announced Annual dividend of INR 13.0000 per share payable on August 30, 2026, ex-date on July 24, 2026 and record date on July 24, 2026. Announcement • May 07
Cravatex Limited to Report Q4, 2026 Results on May 15, 2026 Cravatex Limited announced that they will report Q4, 2026 results on May 15, 2026 Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹5.21 (vs ₹0.97 in 3Q 2025) Third quarter 2026 results: EPS: ₹5.21 (up from ₹0.97 in 3Q 2025). Revenue: ₹413.1m (up 19% from 3Q 2025). Net income: ₹13.5m (up 438% from 3Q 2025). Profit margin: 3.3% (up from 0.7% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Announcement • Feb 03
Cravatex Limited to Report Q3, 2026 Results on Feb 12, 2026 Cravatex Limited announced that they will report Q3, 2026 results on Feb 12, 2026 New Risk • Jan 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹885.3m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (37% accrual ratio). Market cap is less than US$10m (₹885.3m market cap, or US$9.66m). Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹20.18 (vs ₹10.26 in 2Q 2025) Second quarter 2026 results: EPS: ₹20.18 (up from ₹10.26 in 2Q 2025). Revenue: ₹552.4m (down 3.4% from 2Q 2025). Net income: ₹52.2m (up 97% from 2Q 2025). Profit margin: 9.4% (up from 4.6% in 2Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Nov 08
Cravatex Limited to Report Q2, 2026 Results on Nov 14, 2025 Cravatex Limited announced that they will report Q2, 2026 results on Nov 14, 2025 New Risk • Aug 13
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.7% Last year net profit margin: 2.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (267% cash payout ratio). Profit margins are more than 30% lower than last year (1.7% net profit margin). Market cap is less than US$100m (₹1.25b market cap, or US$14.3m). Reported Earnings • Aug 13
First quarter 2026 earnings released: ₹5.29 loss per share (vs ₹1.87 profit in 1Q 2025) First quarter 2026 results: ₹5.29 loss per share (down from ₹1.87 profit in 1Q 2025). Revenue: ₹283.4m (down 3.1% from 1Q 2025). Net loss: ₹13.7m (down 383% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Aug 05
Cravatex Limited to Report Q1, 2026 Results on Aug 12, 2025 Cravatex Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹521, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 29x in the Retail Distributors industry in India. Total returns to shareholders of 35% over the past three years. Upcoming Dividend • Jul 23
Upcoming dividend of ₹12.50 per share Eligible shareholders must have bought the stock before 30 July 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 67% but the company is paying out more than the cash it is generating. Trailing yield: 2.6%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (1.4%). New Risk • Jul 13
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Dividend is not well covered by cash flows (267% cash payout ratio). Market cap is less than US$100m (₹1.19b market cap, or US$13.8m). Reported Earnings • May 23
Full year 2025 earnings released: EPS: ₹18.68 (vs ₹18.68 in FY 2024) Full year 2025 results: EPS: ₹18.68. Revenue: ₹1.84b (down 15% from FY 2024). Net income: ₹48.3m (flat on FY 2024). Profit margin: 2.6% (up from 2.2% in FY 2024). The increase in margin was driven by lower expenses. Declared Dividend • May 21
Dividend increased to ₹12.50 Dividend of ₹12.50 is 317% higher than last year. Ex-date: 30th July 2025 Payment date: 5th September 2025 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (9% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 127% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.5% average weekly change). Profit margins are more than 30% lower than last year (2.3% net profit margin). Market cap is less than US$100m (₹995.2m market cap, or US$11.8m). Announcement • May 10
Cravatex Limited to Report Q4, 2025 Results on May 19, 2025 Cravatex Limited announced that they will report Q4, 2025 results on May 19, 2025 Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹397, the stock trades at a trailing P/E ratio of 26.4x. Average trailing P/E is 27x in the Retail Distributors industry in India. Total returns to shareholders of 3.6% over the past three years. New Risk • Feb 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹856.1m (US$9.82m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹856.1m market cap, or US$9.82m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (2.3% net profit margin). Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹0.97 (vs ₹3.05 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.97 (down from ₹3.05 in 3Q 2024). Revenue: ₹346.7m (down 21% from 3Q 2024). Net income: ₹2.50m (down 68% from 3Q 2024). Profit margin: 0.7% (down from 1.8% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Jan 29
Cravatex Limited to Report Q4, 2025 Results on Feb 10, 2025 Cravatex Limited announced that they will report Q4, 2025 results on Feb 10, 2025 Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹10.26 (vs ₹12.04 in 2Q 2024) Second quarter 2025 results: EPS: ₹10.26 (down from ₹12.04 in 2Q 2024). Revenue: ₹571.7m (down 9.9% from 2Q 2024). Net income: ₹26.5m (down 15% from 2Q 2024). Profit margin: 4.6% (down from 4.9% in 2Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Nov 04
Cravatex Limited to Report Q2, 2025 Results on Nov 13, 2024 Cravatex Limited announced that they will report Q2, 2025 results on Nov 13, 2024 New Risk • Sep 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₹1.50b market cap, or US$17.9m). Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹1.87 (vs ₹1.64 in 1Q 2024) First quarter 2025 results: EPS: ₹1.87 (up from ₹1.64 in 1Q 2024). Revenue: ₹292.6m (down 50% from 1Q 2024). Net income: ₹4.84m (up 14% from 1Q 2024). Profit margin: 1.7% (up from 0.7% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Announcement • Aug 02
Cravatex Limited to Report Q1, 2025 Results on Aug 12, 2024 Cravatex Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹525, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 74% over the past three years. Upcoming Dividend • Jul 23
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 30 July 2024. Payment date: 05 September 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%). Declared Dividend • May 27
Dividend of ₹3.00 announced Shareholders will receive a dividend of ₹3.00. Ex-date: 30th July 2024 Payment date: 5th September 2024 Dividend yield will be 0.7%, which is lower than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (0.4179% earnings payout ratio) and cash flows (2% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 100% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years. Announcement • May 17
Cravatex Limited to Report Q4, 2024 Results on May 24, 2024 Cravatex Limited announced that they will report Q4, 2024 results on May 24, 2024 Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹488, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 43x in the Retail Distributors industry in India. Total returns to shareholders of 74% over the past three years. Reported Earnings • Feb 16
Third quarter 2024 earnings released: EPS: ₹3.05 (vs ₹330 in 3Q 2023) Third quarter 2024 results: EPS: ₹3.05 (down from ₹330 in 3Q 2023). Revenue: ₹437.2m (down 51% from 3Q 2023). Net income: ₹7.88m (down 99% from 3Q 2023). Profit margin: 1.8% (down from 96% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Announcement • Feb 07
Cravatex Limited to Report Q3, 2024 Results on Feb 14, 2024 Cravatex Limited announced that they will report Q3, 2024 results on Feb 14, 2024 Announcement • Feb 01
Cravatex Limited Announces Resignation of Shivkumar Dhalumal Israni as Independent Director Cravatex Limited announced that Dr. Shivkumar Dhalumal Israni (DIN: 00125532) vide his letter dated 31 January, 2024 has resigned as an Independent Director of the Company with effect from closing hours of 31 January, 2024 due to his advanced age and ill-health. that Dr. Shivkumar Dhalumal Israni (DIN: 00125532) vide his letter dated 31 January, 2024 has resigned as an Independent Director of the Company with effect from closing hours of 31 January, 2024 due to his advanced age and ill-health. The resignation letter with reason and confirmation that there are no material reasons for his resignation other than those provided is attached. Reported Earnings • Nov 14
Second quarter 2024 earnings released: EPS: ₹12.04 (vs ₹74.23 loss in 2Q 2023) Second quarter 2024 results: EPS: ₹12.04 (up from ₹74.23 loss in 2Q 2023). Revenue: ₹634.8m (down 63% from 2Q 2023). Net income: ₹31.1m (up ₹222.9m from 2Q 2023). Profit margin: 4.9% (up from net loss in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
First quarter 2024 earnings released: EPS: ₹1.64 (vs ₹42.98 loss in 1Q 2023) First quarter 2024 results: EPS: ₹1.64 (up from ₹42.98 loss in 1Q 2023). Revenue: ₹581.8m (down 65% from 1Q 2023). Net income: ₹4.24m (up ₹115.3m from 1Q 2023). Profit margin: 0.7% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Aug 06
Cravatex Limited to Report Q1, 2024 Results on Aug 14, 2023 Cravatex Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Upcoming Dividend • Jul 21
Upcoming dividend of ₹1.50 per share at 0.4% yield Eligible shareholders must have bought the stock before 28 July 2023. Payment date: 03 September 2023. Payout ratio is a comfortable 0.7% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.4%). Reported Earnings • Jul 14
Full year 2023 earnings released: EPS: ₹228 (vs ₹76.96 loss in FY 2022) Full year 2023 results: EPS: ₹228 (up from ₹76.96 loss in FY 2022). Revenue: ₹5.11b (down 15% from FY 2022). Net income: ₹589.3m (up ₹788.2m from FY 2022). Profit margin: 12% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹228 (vs ₹76.96 loss in FY 2022) Full year 2023 results: EPS: ₹228 (up from ₹76.96 loss in FY 2022). Revenue: ₹5.16b (down 14% from FY 2022). Net income: ₹589.3m (up ₹788.2m from FY 2022). Profit margin: 11% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Additional Executive Director & CFO Divakar Kamath was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹330 (vs ₹14.16 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹330 (up from ₹14.16 loss in 3Q 2022). Revenue: ₹894.1m (down 45% from 3Q 2022). Net income: ₹853.8m (up ₹890.4m from 3Q 2022). Profit margin: 96% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Feb 04
Cravatex Limited to Report Q3, 2023 Results on Feb 13, 2023 Cravatex Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹74.23 loss per share (vs ₹23.37 loss in 2Q 2022) Second quarter 2023 results: ₹74.23 loss per share (further deteriorated from ₹23.37 loss in 2Q 2022). Revenue: ₹1.73b (up 8.7% from 2Q 2022). Net loss: ₹191.8m (loss widened 218% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Nov 13
Second quarter 2023 earnings released: ₹74.23 loss per share (vs ₹23.37 loss in 2Q 2022) Second quarter 2023 results: ₹74.23 loss per share (further deteriorated from ₹23.37 loss in 2Q 2022). Revenue: ₹1.73b (up 8.7% from 2Q 2022). Net loss: ₹191.8m (loss widened 218% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Nov 03
Cravatex Limited to Report First Half, 2023 Results on Nov 11, 2022 Cravatex Limited announced that they will report first half, 2023 results on Nov 11, 2022 Announcement • Oct 20
Metro Brands Limited (NSEI:METROBRAND) signed a share purchase agreement to acquire Cravatex Brands Limited from Cravatex Limited (BSE:509472) and Paragon Partners for an enterprise value of INR 2 billion. Metro Brands Limited (NSEI:METROBRAND) signed a share purchase agreement to acquire Cravatex Brands Limited from Cravatex Limited (BSE:509472) and Paragon Partners for an enterprise value of INR 2 billion on October 19, 2022. The enterprise valuation is subject to pre and post-closing adjustments based on the outstanding debt of CBL as at the completion date. Cravatex Brands generated a revenue of INR 1.57 billion and had net worth of INR -0.41 billion for FY 2021- 22. The transaction has been approved by the Board of Directors of Metro and Cravatex Limited. The acquisition is based on fulfilment of closing conditions by both parties, subject to approval of the shareholders of Cravatex Limited and statutory approvals. The transaction is expected to be completed within ninety (90) days. Announcement • Sep 02
Cravatex Limited Declares Final Dividend for the Financial Year 2021-2022 Cravatex Limited at its Annual General Meeting held on August 30, 2022, declared a final dividend of INR 3 (30%) per share on Equity Shares of INR 10/- each for the financial year 2021-2022. Upcoming Dividend • Aug 15
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 22 August 2022. Payment date: 23 September 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (0.9%). Reported Earnings • Aug 11
Full year 2022 earnings released: ₹76.96 loss per share (vs ₹118 loss in FY 2021) Full year 2022 results: ₹76.96 loss per share (up from ₹118 loss in FY 2021). Revenue: ₹6.04b (up 11% from FY 2021). Net loss: ₹198.9m (loss narrowed 35% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Announcement • Jul 30
Cravatex Limited, Annual General Meeting, Aug 30, 2022 Cravatex Limited, Annual General Meeting, Aug 30, 2022, at 15:30 Indian Standard Time. Announcement • Jul 29
Cravatex Limited Proposes Final Dividend for the Financial Year 2021-22 Cravatex Limited proposed the payment of final dividend of INR 3 per equity share of INR 10 each (30%) for the financial year 2021-22, if approved by the members in the 70th AGM to be held on August 30, 2022. Reported Earnings • Jun 04
Full year 2022 earnings released: ₹76.96 loss per share (vs ₹118 loss in FY 2021) Full year 2022 results: ₹76.96 loss per share (up from ₹118 loss in FY 2021). Revenue: ₹6.04b (up 11% from FY 2021). Net loss: ₹198.9m (loss narrowed 35% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Announcement • May 31
Cravatex Limited Recommends Dividend for the Financial Year Ended 31 March 2022 Cravatex Limited recommended dividend of INR 3.00 per share (30%) on equity shares (listed) of INR 10.00 each for the financial year ended 31 March 2022, for approval of the members at the forthcoming annual general meeting. Announcement • May 24
Cravatex Limited to Report Q4, 2022 Results on May 30, 2022 Cravatex Limited announced that they will report Q4, 2022 results on May 30, 2022 Reported Earnings • Feb 18
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: ₹14.16 loss per share (up from ₹22.71 loss in 3Q 2021). Revenue: ₹1.62b (up 20% from 3Q 2021). Net loss: ₹36.6m (loss narrowed 38% from 3Q 2021). Revenue exceeded analyst estimates by 14%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Aug 11
Upcoming dividend of ₹3.00 per share Eligible shareholders must have bought the stock before 18 August 2021. Payment date: 26 September 2021. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (1.1%). Reported Earnings • Jul 03
Full year 2021 earnings released: ₹118 loss per share (vs ₹33.08 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: ₹5.46b (down 30% from FY 2020). Net loss: ₹306.1m (loss widened 258% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Mar 08
New 90-day high: ₹300 The company is up 6.0% from its price of ₹282 on 08 December 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 23% over the same period. Reported Earnings • Feb 13
Third quarter 2021 earnings released: ₹22.11 loss per share (vs ₹2.57 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹1.35b (down 33% from 3Q 2020). Net loss: ₹58.7m (down ₹65.3m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 78% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Announcement • Feb 05
Cravatex Limited to Report Q3, 2021 Results on Feb 12, 2021 Cravatex Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Jan 27
New 90-day low: ₹250 The company is down 7.0% from its price of ₹268 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 28% over the same period. Is New 90 Day High Low • Nov 05
New 90-day low: ₹254 The company is down 1.0% from its price of ₹257 on 07 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 1.0% over the same period.